Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fatty liver may be a hidden clue for heart trouble

NCT ID NCT06392828

Knowledge-focused Sponsor: IMDEA Food Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether fatty liver disease can be an early warning sign for heart disease, separate from known risk factors. Researchers measured blood markers of blood vessel damage in 63 people aged 50-69 who were already at high risk for heart problems. The goal was to better understand how the liver and heart are connected, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

63 people

The number who actually took part.

Started

Apr 2024

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients attending internal medicine services from the collaborating hospitals will be invited to participate. Physicians responsible for their usual care will check inclusion/exclusion criteria before inviting them to participate. All participants are community-dwelling adults from Community of Madrid, Spain.

Ages

50 to 69 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women * 50-69 years old * With CVD stratification according to ESC 2011 guidelines. * With data to calculate NAFLD scores. Exclusion Criteria: Exclusion Criteria: * Type 1 or type 2 diabetes. * Taking hypoglycemic drugs. * Familiar hypercholesterolemia according to ESC criteria. * Congenital defects on lipid metabolism. * Taking hypolipidemic drugs targeting PCSK9. * Participating on other clinical trials. * Chronic renal disease with filtration rate \< 30 ml/min (RCD degree 4 KDIGO). * Active cancer * Liver disease no NAFLD. * Von Willebrand disease or any other genetic condition with an impact on the plasma concentration of this biomarker. * Systemic autoimmune disease. * Uncapable of giving informed consent. * Any other physical or cognitive condition that could affect the participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder liver disorder metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Non-alcoholic fatty liver disease

Contacts and locations

Locations

  • Clínica Universidad de Navarra

    Madrid, Madrid, 28027, Spain

  • Hospital 12 de Octubre

    Madrid, Madrid, 28041, Spain

  • Hospital Central de la Defensa Gomez Ulla

    Madrid, Madrid, 28047, Spain

  • Hospital HM Montepríncipe

    Madrid, Madrid, 28660, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.